The FDA has accepted lecanemab — the potential heir to Aduhelm’s tarnished fortunes — into its Accelerated Approval pathway, giving the antiamyloid antibody a chance to put Biogen and Eisai back in the Alzheimer’s therapeutics race.
Source: Drug Industry Daily